Resonant Capital Advisors LLC Purchases 764 Shares of Danaher Corporation $DHR

Resonant Capital Advisors LLC raised its position in shares of Danaher Corporation (NYSE:DHR) by 5.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,758 shares of the conglomerate’s stock after acquiring an additional 764 shares during the quarter. Resonant Capital Advisors LLC’s holdings in Danaher were worth $2,920,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of DHR. GAMMA Investing LLC boosted its position in shares of Danaher by 22.2% during the 1st quarter. GAMMA Investing LLC now owns 9,126 shares of the conglomerate’s stock valued at $1,871,000 after purchasing an additional 1,660 shares in the last quarter. Pacific Capital Partners Ltd acquired a new position in Danaher in the first quarter valued at approximately $7,175,000. Golden State Wealth Management LLC boosted its holdings in shares of Danaher by 356.0% during the 1st quarter. Golden State Wealth Management LLC now owns 611 shares of the conglomerate’s stock worth $125,000 after buying an additional 477 shares in the last quarter. Diversified Trust Co grew its position in shares of Danaher by 6.9% during the 1st quarter. Diversified Trust Co now owns 5,861 shares of the conglomerate’s stock worth $1,202,000 after buying an additional 379 shares during the period. Finally, Artemis Investment Management LLP bought a new stake in shares of Danaher in the 1st quarter valued at $13,225,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Up 0.1%

Shares of NYSE:DHR opened at $223.03 on Friday. The business’s 50 day moving average is $202.73 and its 200 day moving average is $198.53. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The stock has a market cap of $157.54 billion, a price-to-earnings ratio of 45.99, a PEG ratio of 3.41 and a beta of 0.77. The company has a quick ratio of 1.22, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 earnings per share for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The business’s revenue was up 4.4% on a year-over-year basis. During the same period last year, the business earned $1.71 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio is presently 26.39%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on DHR shares. Rothschild Redb lowered shares of Danaher from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 8th. Redburn Partners set a $220.00 target price on Danaher in a research note on Wednesday, October 8th. Bank of America dropped their price target on Danaher from $230.00 to $220.00 and set a “buy” rating on the stock in a research note on Monday, September 22nd. Scotiabank raised Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Finally, JPMorgan Chase & Co. upped their target price on Danaher from $260.00 to $270.00 and gave the stock an “overweight” rating in a research report on Wednesday. Eighteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $243.39.

Insider Buying and Selling

In other Danaher news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the completion of the sale, the director owned 20,751 shares in the company, valued at approximately $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.